The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...
Clinical Trials Arena on MSN12d
MacroGenics axes ADC drug following Phase II failure in prostate cancerThe company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...
MedPage Today on MSN14d
End of the Road for Immune Checkpoint Inhibitors in Prostate Cancer?Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...
The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback